LINE-1 hypomethylation is associated with poor outcomes in locoregionally advanced oropharyngeal cancer.
Humans
Tumor Suppressor Protein p53
/ genetics
Papillomavirus Infections
/ complications
Long Interspersed Nucleotide Elements
DNA Methylation
Retrospective Studies
Neoplasm Recurrence, Local
/ genetics
Oropharyngeal Neoplasms
Carcinoma, Squamous Cell
/ metabolism
Squamous Cell Carcinoma of Head and Neck
/ genetics
Prognosis
Head and Neck Neoplasms
/ genetics
DNA methylation
HPV
LINE-1
Oropharyngeal squamous cell carcinoma
p53
Journal
Clinical epigenetics
ISSN: 1868-7083
Titre abrégé: Clin Epigenetics
Pays: Germany
ID NLM: 101516977
Informations de publication
Date de publication:
12 Dec 2022
12 Dec 2022
Historique:
received:
02
08
2022
accepted:
22
11
2022
entrez:
12
12
2022
pubmed:
13
12
2022
medline:
15
12
2022
Statut:
epublish
Résumé
Currently, human papillomavirus (HPV) positivity represents a strong prognostic factor for both reduced risk of relapse and improved survival in patients with oropharyngeal squamous cell carcinoma (OPSCC). However, a subset of HPV-positive OPSCC patients still experience poor outcomes. Furthermore, HPV-negative OPSCC patients, who have an even higher risk of relapse, are still lacking suitable prognostic biomarkers for clinical outcome. Here, we evaluated the prognostic value of LINE-1 methylation level in OPSCC patients and further addressed the relationship between LINE-1 methylation status and p53 protein expression as well as genome-wide/gene-specific DNA methylation. In this study, DNA was extracted from 163 formalin-fixed paraffin-embedded tissue samples retrospectively collected from stage III-IVB OPSCC patients managed with curative intent with up-front treatment. Quantitative methylation-specific PCR revealed that LINE-1 hypomethylation was directly associated with poor prognosis (5-year overall survival-OS: 28.1% for LINE-1 methylation < 35% vs. 69.1% for ≥ 55%; p < 0.0001). When LINE-1 methylation was dichotomized as < 55% versus ≥ 55%, interaction with HPV16 emerged: compared with hypermethylated HPV16-positive patients, subjects with hypomethylated HPV16-negative OPSCC reported an adjusted higher risk of death (HR 4.83, 95% CI 2.24-10.38) and progression (HR 4.54, 95% CI 2.18-9.48). Tumor protein p53 (TP53) gene is often mutated and overexpressed in HPV-negative OPSCC. Since p53 has been reported to repress LINE-1 promoter, we then analyzed the association between p53 protein expression and LINE-1 methylation levels. Following p53 immunohistochemistry, results indicated that among HPV16-negative patients with p53 ≥ 50%, LINE-1 methylation levels declined and remained stable at approximately 43%; any HPV16-positive patient reported p53 ≥ 50%. Finally, DNA methylation analysis demonstrated that genome-wide average methylation level at cytosine-phosphate-guanine sites was significantly lower in HPV16-negative OPSCC patients who relapsed within two years. The subsequent integrative analysis of gene expression and DNA methylation identified 20 up-regulated/hypomethylated genes in relapsed patients, and most of them contained LINE-1 elements in their promoter sequences. Evaluation of the methylation level of LINE-1 may help in identifying the subset of OPSCC patients with bad prognosis regardless of their HPV status. Aberrant LINE-1 hypomethylation might occur along with TP53 mutations and lead to altered gene expression in OPSCC.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Currently, human papillomavirus (HPV) positivity represents a strong prognostic factor for both reduced risk of relapse and improved survival in patients with oropharyngeal squamous cell carcinoma (OPSCC). However, a subset of HPV-positive OPSCC patients still experience poor outcomes. Furthermore, HPV-negative OPSCC patients, who have an even higher risk of relapse, are still lacking suitable prognostic biomarkers for clinical outcome. Here, we evaluated the prognostic value of LINE-1 methylation level in OPSCC patients and further addressed the relationship between LINE-1 methylation status and p53 protein expression as well as genome-wide/gene-specific DNA methylation.
RESULTS
RESULTS
In this study, DNA was extracted from 163 formalin-fixed paraffin-embedded tissue samples retrospectively collected from stage III-IVB OPSCC patients managed with curative intent with up-front treatment. Quantitative methylation-specific PCR revealed that LINE-1 hypomethylation was directly associated with poor prognosis (5-year overall survival-OS: 28.1% for LINE-1 methylation < 35% vs. 69.1% for ≥ 55%; p < 0.0001). When LINE-1 methylation was dichotomized as < 55% versus ≥ 55%, interaction with HPV16 emerged: compared with hypermethylated HPV16-positive patients, subjects with hypomethylated HPV16-negative OPSCC reported an adjusted higher risk of death (HR 4.83, 95% CI 2.24-10.38) and progression (HR 4.54, 95% CI 2.18-9.48). Tumor protein p53 (TP53) gene is often mutated and overexpressed in HPV-negative OPSCC. Since p53 has been reported to repress LINE-1 promoter, we then analyzed the association between p53 protein expression and LINE-1 methylation levels. Following p53 immunohistochemistry, results indicated that among HPV16-negative patients with p53 ≥ 50%, LINE-1 methylation levels declined and remained stable at approximately 43%; any HPV16-positive patient reported p53 ≥ 50%. Finally, DNA methylation analysis demonstrated that genome-wide average methylation level at cytosine-phosphate-guanine sites was significantly lower in HPV16-negative OPSCC patients who relapsed within two years. The subsequent integrative analysis of gene expression and DNA methylation identified 20 up-regulated/hypomethylated genes in relapsed patients, and most of them contained LINE-1 elements in their promoter sequences.
CONCLUSIONS
CONCLUSIONS
Evaluation of the methylation level of LINE-1 may help in identifying the subset of OPSCC patients with bad prognosis regardless of their HPV status. Aberrant LINE-1 hypomethylation might occur along with TP53 mutations and lead to altered gene expression in OPSCC.
Identifiants
pubmed: 36503584
doi: 10.1186/s13148-022-01386-5
pii: 10.1186/s13148-022-01386-5
pmc: PMC9743592
doi:
Substances chimiques
Tumor Suppressor Protein p53
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
171Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : IG-23068
Organisme : Regione Campania
ID : POR Campania FESR 2014/2020 - Azione 1.5, grant GENOMAeSALUTE, CUP B41C17000080007 and RIS3 'La Campania lotta contro il cancro,' grant Rare-Plat-Net, CUP B63D18000380007
Organisme : Centro di Riferimento Oncologico
ID : 5x1000 Intramural Grant
Organisme : Centro di Riferimento Oncologico
ID : 5x1000 Intramural Grant
Organisme : Ministero della Salute
ID : Ricerca Corrente
Informations de copyright
© 2022. The Author(s).
Références
Clin Epigenetics. 2021 Jul 22;13(1):142
pubmed: 34294135
Clin Cancer Res. 2010 Apr 15;16(8):2418-26
pubmed: 20371677
Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):E89-98
pubmed: 23236145
PLoS One. 2011;6(8):e23332
pubmed: 21829728
Genes Cancer. 2016 Mar;7(3-4):136-47
pubmed: 27382437
J Oncol. 2021 Oct 15;2021:9931984
pubmed: 34691179
Cell. 1991 Nov 1;67(3):547-56
pubmed: 1657399
Oncotarget. 2020 Sep 29;11(39):3590-3600
pubmed: 33062195
Am J Pathol. 2014 May;184(5):1280-6
pubmed: 24607009
Nat Rev Cancer. 2017 Jul;17(7):415-424
pubmed: 28642606
Oral Oncol. 2018 Aug;83:127-133
pubmed: 30098768
BMC Cancer. 2019 Jan 14;19(1):64
pubmed: 30642292
Laryngoscope Investig Otolaryngol. 2017 Jan 17;2(1):10-18
pubmed: 28894817
Epigenomics. 2018 Mar;10(3):277-288
pubmed: 29264942
Mod Pathol. 2017 Mar;30(3):382-392
pubmed: 27934876
Clin Cancer Res. 2011 Jul 1;17(13):4225-31
pubmed: 21558408
Sci Rep. 2020 Jun 19;10(1):9970
pubmed: 32561788
Nature. 2015 Jan 29;517(7536):576-82
pubmed: 25631445
Cells. 2020 Sep 02;9(9):
pubmed: 32887319
Radiother Oncol. 2016 Feb;118(2):342-9
pubmed: 26952933
F1000Res. 2014 Jul 01;3:153
pubmed: 25254104
Viruses. 2021 Jul 09;13(7):
pubmed: 34372532
Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):E5526-E5535
pubmed: 29802231
Mod Pathol. 2011 Sep;24(9):1248-53
pubmed: 21552211
Head Neck. 2019 Nov;41(11):3833-3841
pubmed: 31414564
Sci Rep. 2020 Oct 1;10(1):16208
pubmed: 33004905
Mutat Res Rev Mutat Res. 2017 Apr - Jun;772:36-50
pubmed: 28528689
J Natl Cancer Inst. 2016 Jan 28;108(6):djv403
pubmed: 26823521
Lancet. 2019 Jan 5;393(10166):40-50
pubmed: 30449625
Int J Cancer. 2015 Apr 1;136(7):1494-503
pubmed: 24622970
Int J Mol Sci. 2022 Feb 25;23(5):
pubmed: 35269693
Pathol Oncol Res. 2019 Jul;25(3):1047-1058
pubmed: 30099696
Cancer Discov. 2013 Jul;3(7):761-9
pubmed: 23619167
Genome Med. 2017 Apr 5;9(1):33
pubmed: 28381277
Clin Chim Acta. 2019 Jun;493:52-62
pubmed: 30776360
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
N Engl J Med. 2007 Dec 20;357(25):2552-61
pubmed: 18094376
Acta Otolaryngol. 2021 Jul;141(7):724-728
pubmed: 34101529
Nat Commun. 2019 Sep 19;10(1):4278
pubmed: 31537801
Oncotarget. 2016 Oct 4;7(40):64910-64920
pubmed: 27626311
J Surg Oncol. 2021 Nov;124(6):962-966
pubmed: 34595766
Cancer. 2021 Sep 1;127(17):3092-3106
pubmed: 33957701
Clin Epigenetics. 2017 Jan 13;9:1
pubmed: 28149329
Thorac Cancer. 2022 Feb;13(3):369-379
pubmed: 34951127
Nat Genet. 2009 May;41(5):563-71
pubmed: 19377475
Med Sci Monit. 2018 May 09;24:3024-3033
pubmed: 29739919
Clin Epigenetics. 2017 Nov 28;9:124
pubmed: 29209433
Clin Epigenetics. 2017 May 30;9:58
pubmed: 28572862
Gut. 2014 Apr;63(4):635-46
pubmed: 23704319
Acta Oncol. 2008;47(4):600-7
pubmed: 18465328
Genes Dev. 2016 Jan 1;30(1):64-77
pubmed: 26701264
PLoS Genet. 2010 Apr 22;6(4):e1000917
pubmed: 20421991
Oral Oncol. 2020 Dec;111:104981
pubmed: 32873464
World J Surg Oncol. 2021 Jan 26;19(1):29
pubmed: 33499882
Nat Rev Genet. 2011 Feb;12(2):123-35
pubmed: 21221116
Oral Oncol. 2020 Jan;100:104488
pubmed: 31835137
Front Cell Dev Biol. 2020 Aug 07;8:657
pubmed: 32850797
FEBS J. 2022 Mar;289(5):1160-1179
pubmed: 33471418
Cancer Genet. 2020 Jun;244:21-29
pubmed: 32088612
J Cell Biochem. 2016 Dec;117(12):2682-2692
pubmed: 27166782
Genes Dev. 2020 Nov 1;34(21-22):1439-1451
pubmed: 33060137
Clin Epigenetics. 2019 May 14;11(1):77
pubmed: 31088544